DLL3 and small cell lung carcinoma: For example, recent data indicated that Delta-like protein 3 (DLL3), including an antibody–drug conjugate, a bispecific T cell engager, and a chimeric antigen receptor (CAR)-T cell construct, can target SCLC-A subtypes [23].